Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;10(10):973-6.
doi: 10.1038/nmeth.2600. Epub 2013 Jul 25.

RNA-guided Gene Activation by CRISPR-Cas9-based Transcription Factors

Affiliations
Free PMC article

RNA-guided Gene Activation by CRISPR-Cas9-based Transcription Factors

Pablo Perez-Pinera et al. Nat Methods. .
Free PMC article

Abstract

Technologies for engineering synthetic transcription factors have enabled many advances in medical and scientific research. In contrast to existing methods based on engineering of DNA-binding proteins, we created a Cas9-based transactivator that is targeted to DNA sequences by guide RNA molecules. Coexpression of this transactivator and combinations of guide RNAs in human cells induced specific expression of endogenous target genes, demonstrating a simple and versatile approach for RNA-guided gene activation.

Figures

Figure 1
Figure 1
RNA-guided activation of the human IL1RN gene by dCas9-VP64. (a) An RNA-guided transcriptional activator was created by fusing dCas9 (D10A/H840A) to the VP64 transactivation domain. dCas9-VP64 recognizes genomic target sites through the hybridization of a guide RNA (gRNA) to a 20 bp target sequence. (b) The structure of dCas9-VP64 is shown, including Flag and HA epitope tags, two nuclear localization signals (NLS), and the positions of the RuvC- and HNH-like endonuclease domains that target the noncomplementary and complementary DNA strands, respectively, if not inactivated by the mutations D10A and H840A.(c) Expression plasmids for four gRNAs or crRNA/tracrRNAs targeted to sequences in the IL1RN promoter were co-transfected with the dCas9-VP64 expression plasmid into HEK293T cells. Activation of IL1RN expression was assessed by qRT-PCR. (d) The four gRNA expression plasmids were co-transfected with dCas9-VP64 individually or in combination. Robust gene activation was observed by qRT-PCR only in response to the combination of gRNAs. (e) Activation of IL1RN expression was confirmed by assessing secretion of the IL-1ra gene product into the media by ELISA. IL-1ra was only detectable above background in three of the six samples treated with the combination of gRNAs. For (c-e), data are shown as the mean ± s.e.m (n = 3 independent experiments). Treatment with the combination of gRNAs was statistically different than all other treatments (*P ≤ 0.05) by Tukey’s test. (f) RNA-seq was performed on samples treated with empty expression vector (n = 2) or co-transfected with the expression plasmids for dCas9-VP64 and the four gRNAs targeting IL1RN (n = 2). The only statistically significant changes in gene expression between these treatments were an increase in the four IL1RN isoforms (false discovery rate ≤ 3 × 10−4) and a decrease in IL32 (false discovery rate = 0.03).
Figure 2
Figure 2
RNA-guided activation of human genes relevant to cell and gene therapy, genetic reprogramming, and regenerative medicine. HEK293T cells were transfected with the dCas9-VP64 expression plasmid and four gRNAs individually or in combination. Target gene expression was measured by qRT-PCR and normalized to GAPDH mRNA levels. Data are shown as the mean ± s.e.m (n = 3 independent experiments). Treatment with the combination of gRNAs was statistically different than all other treatments (*P < 0.05) by Tukey’s test.

Similar articles

See all similar articles

Cited by 381 articles

See all "Cited by" articles

References

    1. Rebar EJ, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med. 2002;8:1427–1432. - PubMed
    1. Graslund T, Li X, Magnenat L, Popkov M, Barbas CF., 3rd Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. J Biol Chem. 2005;280:3707–3714. - PubMed
    1. Beltran A, et al. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 2007;26:2791–2798. - PubMed
    1. Bartsevich VV, Miller JC, Case CC, Pabo CO. Engineered zinc finger proteins for controlling stem cell fate. Stem Cells. 2003;21:632–637. - PubMed
    1. Bultmann S, et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res. 2012;40:5368–5377. - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources

Feedback